Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive

Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive. Randomized Clinical, Not Masked, Trial Comparing DRVr3TC, ABC3TC (Kivexa) RPV, or EVG COBI FTC TDF (Stribild) for 48 Weeks

The main objective of this study is to know the efficiency (costeffectiveness) at 48 weeks of initiation of antiretroviral treatment. three strategies of treatment.

Secondary objectives:

• patients with virologic response ratio at 48 weeks (less than 50 plasma viral load)
• Change in the number of CD4 cells at 48 weeks
• Change in body composition and mineral density bone (body and lumbar) measurement with DEXA (bone mineral density scan) at 48 weeks
• Change in markers of renal function (creatinine clearance, glomerular filtration rate - eGFR - estimated rate) and renal tubular function at 48 weeks
• Rate of mortality and clinical progression at 48 weeks
• general tolerability and safety: adverse events (AA) and serious AA description

Inclusion Criteria:

• 1-negative pregnancy test in women of childbearing age
• 2- stable HIV-1 infection clinically and not take antiretroviral therapy
• 3- viral load HIV <100,000 copies
• 4- CD4 cells >100 cels/mm3
• 5- Glomerular filtration >70mlmin
• 6- have a negative HLA B5701
• 7-.patients should have given informed written consent
• 8- in the opinion of the investigator, be able to follow the design of the Protocol visits

Exclusion Criteria:

• 1-. Patients who had virologic failure with any antiretroviral therapy
• 2- evidence of prior mutations of the study drugs
• 3- use of any anti-retroviral treatment in the 6 months prior to the entry of the study
• 4- contraindication to the drugs study
• 5- any condition that does not allow to ensure the correct compliance to the study
• 6- uncontrolled previous psychiatric illness
• 7- Current or active addiction or alcoholism